DK200000687A - Middel til forsøgelse af afgivelsen af cerebral acetylcholin - Google Patents
Middel til forsøgelse af afgivelsen af cerebral acetylcholin Download PDFInfo
- Publication number
- DK200000687A DK200000687A DK200000687A DKPA200000687A DK200000687A DK 200000687 A DK200000687 A DK 200000687A DK 200000687 A DK200000687 A DK 200000687A DK PA200000687 A DKPA200000687 A DK PA200000687A DK 200000687 A DK200000687 A DK 200000687A
- Authority
- DK
- Denmark
- Prior art keywords
- delivery
- attempting
- agent
- cerebral acetylcholine
- cerebral
- Prior art date
Links
- 230000002490 cerebral effect Effects 0.000 title description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 title description 2
- 229960004373 acetylcholine Drugs 0.000 title description 2
- DZTVZKSCFQIBMV-UHFFFAOYSA-N 4-[(4-methoxybenzoyl)amino]butanoic acid Chemical compound COC1=CC=C(C(=O)NCCCC(O)=O)C=C1 DZTVZKSCFQIBMV-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 208000017164 Chronobiology disease Diseases 0.000 description 2
- 231100000871 behavioral problem Toxicity 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
PATENTKRAV 1. Anvendelse af N-anisoyl-GABA eller p-anissyre til fremstilling af et farmaceutisk præparat, der omfatter N-anisoyl-GABA eller p-anissyre, til at forøge afgivelsen af cerebral acet-ylcholin. 2. Anvendelse ifølge krav 1, hvor det farmaceutiske præparat er til behandling af døgn-rytmeforstyrrelser, søvnforstyrrelser, lidelser forbundet med opmærksomhedssvigt og adfærdsproblemer. 3. Anvendelse ifølge krav 1 eller krav 2, hvor N-anisoyl-GABA eller p-anissyre som effektiv bestanddel foreligger i en enhedsdosis på fra 1 til 300 mg/kg pr. voksen pr. dag. 4. Farmaceutisk præparat til at forøge afgivelsen af cerebral acetylcholin, hvilket præparat omfatter N-anisoyl-GABA eller p-anissyre som effektiv bestanddel og en terapeutisk inert bærer. 5. Farmaceutisk præparat ifølge krav 4 til behandling af døgnrytmeforstyrrelser, søvnforstyrrelser, lidelser forbundet med opmærksomhedssvigt og adfærdsproblemer. 6. Farmaceutisk præparat ifølge krav 4 eller krav 5, hvor den aktive bestanddel N-anisoyl-GABA eller p-anissyre administreres i en dosis på fra 1 til 300 mg/kg pr. voksen pr. dag.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99108223 | 1999-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK200000687A true DK200000687A (da) | 2000-10-28 |
Family
ID=8238054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK200000687A DK200000687A (da) | 1999-04-27 | 2000-04-25 | Middel til forsøgelse af afgivelsen af cerebral acetylcholin |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20030073744A1 (da) |
| JP (1) | JP2000309529A (da) |
| KR (1) | KR100372906B1 (da) |
| CN (1) | CN1277019A (da) |
| AR (1) | AR023763A1 (da) |
| AT (1) | AT408836B (da) |
| AU (1) | AU3011300A (da) |
| BE (1) | BE1013314A3 (da) |
| BR (1) | BR0002381A (da) |
| CA (1) | CA2307022A1 (da) |
| DE (1) | DE10020237A1 (da) |
| DK (1) | DK200000687A (da) |
| ES (1) | ES2176078A1 (da) |
| FI (1) | FI20000977A (da) |
| FR (1) | FR2792833B1 (da) |
| GB (1) | GB2351662A (da) |
| GR (1) | GR1003591B (da) |
| IE (1) | IE20000308A1 (da) |
| IT (1) | IT1318490B1 (da) |
| NL (1) | NL1015043C2 (da) |
| PT (1) | PT102456B (da) |
| SE (1) | SE0001499L (da) |
| TR (1) | TR200001133A2 (da) |
| ZA (1) | ZA200002041B (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5273731B2 (ja) * | 2009-08-11 | 2013-08-28 | 独立行政法人産業技術総合研究所 | 生体リズムの制御剤 |
| NZ777148A (en) * | 2018-11-13 | 2024-05-31 | Xianfeng Peng | Use of acylated derivative of amino acid in preparing animal feed additive |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU21107A3 (es) * | 1978-02-10 | 1988-02-01 | Hoffmann La Roche | Pyrrolidines derivatives |
| JPH1081626A (ja) * | 1996-09-06 | 1998-03-31 | Kamiyama:Kk | チロシナーゼ活性阻害剤 |
| JPH1081607A (ja) * | 1996-09-06 | 1998-03-31 | Kamiyama:Kk | 抗菌剤 |
-
2000
- 2000-04-21 IT IT2000MI000914A patent/IT1318490B1/it active
- 2000-04-21 FR FR0005180A patent/FR2792833B1/fr not_active Expired - Fee Related
- 2000-04-24 KR KR10-2000-0021630A patent/KR100372906B1/ko not_active IP Right Cessation
- 2000-04-24 GR GR20000100145A patent/GR1003591B/el unknown
- 2000-04-24 JP JP2000121904A patent/JP2000309529A/ja active Pending
- 2000-04-25 AT AT0071600A patent/AT408836B/de not_active IP Right Cessation
- 2000-04-25 DE DE10020237A patent/DE10020237A1/de not_active Withdrawn
- 2000-04-25 DK DK200000687A patent/DK200000687A/da not_active Application Discontinuation
- 2000-04-25 AR ARP000101934A patent/AR023763A1/es not_active Application Discontinuation
- 2000-04-25 ZA ZA200002041A patent/ZA200002041B/xx unknown
- 2000-04-25 IE IE20000308A patent/IE20000308A1/en not_active IP Right Cessation
- 2000-04-25 GB GB0010049A patent/GB2351662A/en not_active Withdrawn
- 2000-04-26 TR TR2000/01133A patent/TR200001133A2/xx unknown
- 2000-04-26 BR BR0002381-7A patent/BR0002381A/pt not_active IP Right Cessation
- 2000-04-26 ES ES200001063A patent/ES2176078A1/es active Pending
- 2000-04-26 PT PT102456A patent/PT102456B/pt not_active IP Right Cessation
- 2000-04-26 BE BE2000/0294A patent/BE1013314A3/fr not_active IP Right Cessation
- 2000-04-26 FI FI20000977A patent/FI20000977A/fi not_active IP Right Cessation
- 2000-04-26 AU AU30113/00A patent/AU3011300A/en not_active Abandoned
- 2000-04-26 CA CA002307022A patent/CA2307022A1/en not_active Abandoned
- 2000-04-26 SE SE0001499A patent/SE0001499L/ unknown
- 2000-04-27 CN CN00118155A patent/CN1277019A/zh active Pending
- 2000-04-27 NL NL1015043A patent/NL1015043C2/nl not_active IP Right Cessation
-
2002
- 2002-12-04 US US10/309,434 patent/US20030073744A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002522485A5 (da) | ||
| JP2002532392A5 (da) | ||
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| CY1111088T1 (el) | Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση | |
| ATE424810T1 (de) | Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung | |
| ATE146677T1 (de) | Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit | |
| JP2004506682A5 (da) | ||
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| RU2009123536A (ru) | Стабильные парентеральные составы, включающие ингибиторы pcb на основе бензодиазепина | |
| SK7532002A3 (en) | Pharmaceutical formulations containing zolmitriptan | |
| BE900749A (fr) | Medicament microencapsule dans une matrice sucree. | |
| US20150352038A1 (en) | A dosage form for administering an active principle for accelerated sleep induction and/or for treating sleep disorders and/or for treating a central nervous system disorder | |
| RU2002122084A (ru) | Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных растройств | |
| CH670763A5 (da) | ||
| JP2002540148A5 (da) | ||
| RU2001118854A (ru) | Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний | |
| DK200000687A (da) | Middel til forsøgelse af afgivelsen af cerebral acetylcholin | |
| ATE192926T1 (de) | Flavopereirine enthaltende zusammensetzung und ihre anwendung in der behandlung gegen hiv-viren | |
| JPH01261334A (ja) | アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法 | |
| KR860003018A (ko) | 1-β-D-리보푸라노실-1,2,4-트리아졸-3-카르복사미드를 이용한 인체의 비루스성 질환의 의학적 치료방법 | |
| AR006202A1 (es) | Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene | |
| DE69803670D1 (de) | Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung | |
| EP0402208B1 (fr) | Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique | |
| ATE302010T1 (de) | Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus | |
| ES2287512T3 (es) | Utilizacion combinada de metilfenidato y melatonina para el tratamiento de la enfermedad de hiperactividad con deficit de atencion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHS | Application shelved for other reasons than non-payment |